Global Bacterial Conjunctivitis Drugs Market 2016-2020

Outlook of the global bacterial conjunctivitis drugs market

Technavio’s market research analyst predicts the global bacterial conjunctivitis drugs market to grow moderately at a CAGR of approximately 3% during the forecast period. Factors such as the growing awareness among consumers and the widespread availability of multiple treatment options will spur the prospects for growth in this market. Much of this awareness is brought about by the organizations that conduct awareness campaigns about the disease.

The development of multi-drug resistant variants, which is resulting in the augmented use of drugs, is expected to boost market growth during the forecast period. Microbes such as Streptococcus or Staphylococcus are responsible for bacterial conjunctivitis. These microbes change themselves chemically to develop resistance to the drugs. Since this resistance develops due to the irrational use of antibiotics, it may lead to severe complications in the body of the patients. Patients are thus expected to take up more medications such as corticosteroids and higher doses of antibiotics for the treatment of such diseases. This augmented use of drugs like corticosteroids and antibiotics for the treatment of bacterial conjunctivitis will propel the prospects for growth in this market.

Segmentation by drug class and analysis of the bacterial conjunctivitis drugs market

• Fluoroquinolones
• Aminoglycosides
• Macrolides

The fluoroquinolones segment is expected to dominate the market during the forecast period. The broad spectrum of activity and increased efficacy of these drugs, even at lower concentrations, are the main factors fueling the demand for fluoroquinolones among the consumers.

Geographical segmentation of the bacterial conjunctivitis drugs market

• Americas
• APAC
• EMEA

In this market research, analysts have estimated the Americas to account for around 49% of the overall market share and is expected to grow at a CAGR of approximately 3% during the forecast period. The presence of a well-developed healthcare system in this region and the widespread availability of reimbursement facilities are the primary factors that impel market growth in this region.

Competitive landscape and key vendors

The global bacterial conjunctivitis drugs market is highly fragmented because of the presence of numerous small and large vendors. The vendors in this market compete on the basis of price, quality, and innovation. The high level of vendor competition in this market has led to an increase in the number of mergers and acquisitions, wherein smaller entities are being acquired by or are being merged with, major players.

Leading vendors in the market are -

• Akorn
• Alcon
• Allergan
• Bausch & Lomb

Other prominent vendors in the market include Bayer, Daiichi Sankyo, Roche, InSite Vision, Merck, Nicox, Novartis, Perrigo Company, Pfizer, Santen, Shire, and Valeant.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global bacterial conjunctivitis drugs market?
• What are the key market trends impacting the growth of the bacterial conjunctivitis drugs market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the vendors in the global bacterial conjunctivitis drugs?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the bacterial conjunctivitis drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Conjunctivitis Market 2015-2019
• Global Ophthalmic Therapeutic Market 2015-2019
• Global Retinal Surgery Devices Market 2015-2019
• Global Ophthalmic Diagnostic Devices Market 2014-2018